These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529 [TBL] [Abstract][Full Text] [Related]
9. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP; N Engl J Med; 2024 Sep; 391(10):885-898. PubMed ID: 38820078 [TBL] [Abstract][Full Text] [Related]
10. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525 [TBL] [Abstract][Full Text] [Related]
11. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212 [TBL] [Abstract][Full Text] [Related]
12. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach. García Molina A Farm Hosp; 2024; 48(5):T222-T229. PubMed ID: 39013681 [TBL] [Abstract][Full Text] [Related]
13. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach. Garcia Molina A Farm Hosp; 2024; 48(5):222-229. PubMed ID: 38679535 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Cortes JE; Kantarjian HM; Brümmendorf TH; Kim DW; Turkina AG; Shen ZX; Pasquini R; Khoury HJ; Arkin S; Volkert A; Besson N; Abbas R; Wang J; Leip E; Gambacorti-Passerini C Blood; 2011 Oct; 118(17):4567-76. PubMed ID: 21865346 [TBL] [Abstract][Full Text] [Related]
17. Bosutinib for the treatment of chronic myeloid leukemia. Doan V; Wang A; Prescott H Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937 [TBL] [Abstract][Full Text] [Related]
18. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340 [TBL] [Abstract][Full Text] [Related]
19. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154 [TBL] [Abstract][Full Text] [Related]
20. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]